Social Anxiety Disorder (SAD)

The short version

●Social anxiety disorder (SAD) is a DSM-5-TR anxiety disorder defined by marked, persistent fear of social or performance situations in which one is exposed to possible scrutiny, with the fear out of proportion to actual social threat.
●Two clinically useful subtypes: generalized SAD (most social situations trigger anxiety) and performance-only SAD (anxiety restricted to public speaking or specific performance contexts). Treatment selection differs.
●First-line treatments: SSRIs (paroxetine, sertraline, escitalopram) and cognitive-behavioral therapy with exposure components. Effect sizes are large in trials; clinical-practice outcomes more modest.
●For performance-only SAD: beta-blockers (propranolol) on an as-needed basis are effective and avoid daily medication. Generalized SAD requires daily pharmacotherapy.
●Treatment-resistant social anxiety is common. Many patients drop out of CBT before completing exposure work, and SSRI response rates are 40-60% with smaller remission rates.
●Ketamine's evidence base in SAD specifically is preliminary — the Mills 2025 BJPsych Ket-Adolescent analysis showed measurable anxiety reduction across diagnostically heterogeneous groups, but a SAD-specific RCT has not been done.

Clinical definition

DSM-5-TR criteria for SAD: marked fear or anxiety about one or more social situations involving possible scrutiny (conversations, meeting unfamiliar people, being observed eating or drinking, or performing); the social situations almost always provoke fear; they are actively avoided or endured with intense distress; the fear is out of proportion to actual social threat; symptoms persist 6+ months and cause clinically significant distress or impairment. The "performance only" specifier applies when fear is restricted to public speaking or performing. SAD typically begins in adolescence (mean age of onset 13), has a chronic course without treatment, and predicts substantial functional impairment in education, occupation, and relationships. Lifetime prevalence is approximately 12% in U.S. epidemiological samples — among the most prevalent anxiety disorders. Comorbidity with depression, alcohol use disorder, and other anxiety disorders is the rule rather than the exception.

How it differs from related conditions

vs. Shyness / introversion

Non-pathological. Shy people may prefer fewer social interactions but do not experience the persistent fear of judgment, marked avoidance, or functional impairment required for SAD. The threshold is functional: impairment in work, school, or relationships meaningful to the patient.

vs. Panic disorder

Panic disorder centers on the panic attacks themselves and the fear of having them; SAD centers on social scrutiny. Patients may have panic-like episodes in social situations (situationally bound), but the fear content (judgment vs death/loss of control) distinguishes them. Both can co-occur.

vs. Avoidant personality disorder (AVPD)

Substantial overlap — many patients meet both. AVPD adds pervasive feelings of inadequacy, hypersensitivity to negative evaluation across contexts (not just social), and a stable trait pattern beginning in early adulthood. Treatment implications differ: AVPD typically requires longer-duration therapy with attention to interpersonal patterns.

vs. Body dysmorphic disorder (BDD)

BDD patients avoid social situations because of perceived appearance flaws specifically; SAD patients avoid because of general fear of judgment. Many patients have features of both. Distinguishing matters because BDD has specific treatment protocols and often higher suicide risk.

First-line treatments

SSRIs (paroxetine, sertraline, escitalopram, fluvoxamine)

FDA-approved indications and large-trial evidence in generalized SAD. Paroxetine and sertraline have the most specific approval; escitalopram has growing evidence with better tolerability. Onset of effect is 4-8 weeks; full benefit at 12 weeks. Response rates approximately 50-60%; remission rates 25-35%. Continue 6-12 months minimum after response to reduce relapse risk.

SNRIs (venlafaxine)

Venlafaxine XR has FDA approval and trial evidence in SAD comparable to SSRIs. Useful when SSRI trials fail or for patients with comorbid depression with melancholic features. Same general onset and duration considerations as SSRIs.

Cognitive-behavioral therapy with exposure (CBT-E)

First-line non-pharmacological treatment. The active ingredients are exposure (deliberately entering feared social situations and remaining until anxiety attenuates) plus cognitive restructuring of feared outcomes. Group format adds a built-in exposure dimension. Heimberg's manualized SAD-CBT has the most published evidence. Treatment course typically 12-16 weekly sessions.

Beta-blockers (propranolol) for performance-only SAD

For patients whose anxiety is restricted to performance contexts (public speaking, musical performance, presentations), as-needed propranolol 10-40mg 30-60 minutes before the event blocks the peripheral autonomic manifestations (tremor, tachycardia, sweating). Does not treat the cognitive-affective fear directly but often breaks the feedback loop between physical sensations and escalating fear. Avoid in asthma, heart block, severe bradycardia.

Benzodiazepines (limited role)

Clonazepam has trial evidence in SAD but is generally avoided as first-line because of dependence risk and the high comorbidity with alcohol use disorder in this population. Useful in narrow contexts: short-term bridge while SSRI takes effect, or single-occasion use for an unavoidable high-stakes performance situation. Should not be daily long-term in SAD.

Acceptance and Commitment Therapy (ACT)

ACT shifts focus from anxiety reduction to values-driven action despite anxiety. Useful for SAD patients who have plateaued in standard CBT or for whom exposure-based work is psychologically untenable as initially framed. Effect sizes in published trials are comparable to CBT-E for many patients.

Gabapentin or pregabalin (off-label)

Pregabalin has trial evidence in generalized anxiety disorder and growing use in SAD. May be considered when SSRIs and CBT have failed. Side effect profile (sedation, weight gain, cognitive blunting) limits enthusiasm; misuse potential is lower than benzodiazepines but non-zero.

When standard treatments fail

A meaningful minority of SAD patients do not respond to adequate trials of first-line SSRI + CBT-E with exposure. The typical sequence after first SSRI failure: switch to a second SSRI (different molecule, not just dose increase) for 12 weeks → switch to SNRI (venlafaxine XR) → consider augmentation with pregabalin or clonazepam (short course) → consider ACT or schema therapy if standard CBT has plateaued → consider rapid-acting options including ketamine for the depressive symptoms that often accompany treatment-resistant SAD. CBT non-response often reflects exposure non-completion rather than true treatment resistance — patients drop out before reaching the most therapeutic exposures. Re-engagement with a different therapist or a more graduated exposure plan can rescue apparent CBT failure.

Where ketamine fits

Ketamine is not first-line for social anxiety. The published evidence base in SAD specifically is small — most ketamine trials target depression or PTSD, with SAD patients included only when comorbid. The Mills 2025 BJPsych analysis of ketamine across diagnostically heterogeneous depressive cohorts showed measurable anxiety reduction alongside the depression effect, supporting the broader anxiolytic mechanism, but a SAD-specific RCT has not been done. Clinically, ketamine becomes relevant for SAD patients with concurrent treatment-resistant depression (a very common presentation) or for patients who have failed adequate trials of multiple SSRIs/SNRIs plus CBT-E. The rapid-acting effect can also lower exposure-therapy avoidance — some integration models pair ketamine sessions with concurrent CBT-E to leverage the post-session neuroplastic window for exposure work.

Where this fits with Tovani

Tovani treats SAD when standard treatments have been adequately tried, typically after failure of at least two SSRI/SNRI trials at adequate dose plus a course of evidence-based CBT or ACT. Eligibility screening captures treatment history. Many patients with SAD have concurrent depression; the depression is typically the primary indication and the SAD is addressed via the broader anxiolytic effect. Patients with isolated SAD (no comorbid depression) and no adequate first-line trials are usually referred back to first-line care before ketamine is appropriate.

Check eligibility The science behind ketamine

Frequently asked

Is social anxiety just shyness?

No. Shyness is a non-pathological temperamental trait; social anxiety disorder is a clinical condition with persistent fear out of proportion to actual social threat, marked avoidance, and functional impairment. The threshold is whether the anxiety interferes with work, school, or relationships you want to engage in. Most shy people are not impaired; SAD patients are.

Do I have to take medication forever?

Not necessarily. For generalized SAD, current guidelines recommend continuing SSRIs for at least 6-12 months after response, then considering taper if symptoms remain in remission. Many patients eventually discontinue; some need long-term treatment. CBT-E gains tend to be more durable than medication-only gains, which is why combined treatment is recommended.

I have social anxiety only for public speaking. Do I need daily medication?

Probably not. Performance-only SAD often responds well to as-needed beta-blocker (propranolol) 30-60 minutes before the event. This avoids daily pharmacotherapy and addresses the autonomic component effectively. Cognitive-behavioral work on the underlying performance anxiety adds durability.

Can ketamine help my social anxiety?

The evidence base is preliminary. Ketamine has measurable anxiolytic effects alongside its antidepressant effect, but a social-anxiety-specific RCT has not been done. Ketamine is more reasonably considered when SAD coexists with treatment-resistant depression, or after adequate trials of SSRIs and CBT have failed. Not first-line for isolated SAD.

What if I can't bring myself to do exposure therapy?

Exposure-avoidance is itself a symptom of SAD. Strategies include: starting with imagined exposure before in vivo work, building a graduated hierarchy (least feared first), using a group format (built-in exposure with structure), and pairing exposure with anti-anxiety medication during the active phase. Some patients also benefit from acceptance-based approaches (ACT) that reframe the goal as values-driven action rather than anxiety elimination.

References

Bandelow B et al. 2017, Dialogues in Clinical Neuroscience — Comprehensive review of treatment of anxiety disorders including social anxiety disorder — evidence base for SSRIs, SNRIs, beta-blockers, benzodiazepines, and CBT as first-line and second-line options. (PMID 28867934)
Bandelow B et al. 2023, World Journal of Biological Psychiatry — WFSBP guidelines for pharmacological treatment of anxiety, obsessive-compulsive, and PTSD disorders — current first-line, second-line, and rescue treatments for social anxiety disorder including pregabalin and combination approaches. (PMID 35900161)
Mills NT et al. 2025, British Journal of Psychiatry — Ketamine for adult depression study — measurable anxiety reduction alongside depression effect in diagnostically heterogeneous cohort, supporting broader anxiolytic mechanism with relevance to comorbid social anxiety. (PMID 39763417)
Furmark T et al. 2025, Frontiers in Psychology — Review of SSRI evidence in social anxiety disorder — placebo-controlled effect sizes, response and remission rates, and durability considerations in long-term treatment. (PMID 40420982)

Last reviewed by Dr. Ben Soffer, DO on May 27, 2026. This page is educational and not a substitute for clinical evaluation. A physician determines whether ketamine therapy is appropriate for your specific situation.